US20220023197A1 - Composition for treating or preventing skin pigmentation - Google Patents
Composition for treating or preventing skin pigmentation Download PDFInfo
- Publication number
- US20220023197A1 US20220023197A1 US17/298,440 US201917298440A US2022023197A1 US 20220023197 A1 US20220023197 A1 US 20220023197A1 US 201917298440 A US201917298440 A US 201917298440A US 2022023197 A1 US2022023197 A1 US 2022023197A1
- Authority
- US
- United States
- Prior art keywords
- fibroblasts
- pigmentation
- skin
- model
- puva
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000012641 Pigmentation disease Diseases 0.000 title claims abstract description 123
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 140
- 230000019612 pigmentation Effects 0.000 claims abstract description 48
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 72
- 210000001519 tissue Anatomy 0.000 claims description 33
- 230000009758 senescence Effects 0.000 claims description 26
- 230000006378 damage Effects 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 15
- 230000002500 effect on skin Effects 0.000 claims description 13
- 208000003351 Melanosis Diseases 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 6
- 206010014970 Ephelides Diseases 0.000 claims description 5
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 101000903927 Aspergillus oryzae (strain ATCC 42149 / RIB 40) Beta-galactosidase A Proteins 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 claims description 4
- 206010008570 Chloasma Diseases 0.000 claims description 3
- 206010039796 Seborrhoeic keratosis Diseases 0.000 claims description 3
- 230000003187 abdominal effect Effects 0.000 claims description 3
- 210000001217 buttock Anatomy 0.000 claims description 3
- 230000022131 cell cycle Effects 0.000 claims description 3
- 238000002659 cell therapy Methods 0.000 claims description 3
- 210000000038 chest Anatomy 0.000 claims description 3
- 210000004195 gingiva Anatomy 0.000 claims description 3
- 210000002200 mouth mucosa Anatomy 0.000 claims description 3
- 210000004761 scalp Anatomy 0.000 claims description 3
- 201000003385 seborrheic keratosis Diseases 0.000 claims description 3
- 230000003248 secreting effect Effects 0.000 claims description 3
- 210000004207 dermis Anatomy 0.000 abstract description 41
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 52
- 210000002615 epidermis Anatomy 0.000 description 40
- 210000002752 melanocyte Anatomy 0.000 description 32
- 238000000034 method Methods 0.000 description 24
- -1 IL-1α Proteins 0.000 description 23
- 238000012258 culturing Methods 0.000 description 21
- 210000002510 keratinocyte Anatomy 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 14
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000000049 pigment Substances 0.000 description 9
- 239000011668 ascorbic acid Substances 0.000 description 8
- 235000010323 ascorbic acid Nutrition 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 239000008187 granular material Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- 238000012758 nuclear staining Methods 0.000 description 6
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical group C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108010014258 Elastin Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- 102000016942 Elastin Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 229920002549 elastin Polymers 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 101000796203 Homo sapiens L-dopachrome tautomerase Proteins 0.000 description 3
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000012261 overproduction Methods 0.000 description 3
- 239000003504 photosensitizing agent Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 2
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100262697 Mus musculus Axl gene Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical group OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical group C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 229940028444 muse Drugs 0.000 description 2
- 108010008217 nidogen Proteins 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000000437 stratum spinosum Anatomy 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000010981 turquoise Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- DZKLSFQAIYUHCL-UHFFFAOYSA-N 1,2-dihydroxy-2-(hydroxymethyl)icosan-3-one Chemical compound CCCCCCCCCCCCCCCCCC(=O)C(O)(CO)CO DZKLSFQAIYUHCL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100038778 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 101800001382 Betacellulin Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 1
- 101001069913 Bos taurus Growth-regulated protein homolog beta Proteins 0.000 description 1
- 101001069912 Bos taurus Growth-regulated protein homolog gamma Proteins 0.000 description 1
- 102100036841 C-C motif chemokine 1 Human genes 0.000 description 1
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 1
- 102100023700 C-C motif chemokine 16 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036845 C-C motif chemokine 22 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 1
- 101710112538 C-C motif chemokine 27 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
- 101710085504 C-X-C motif chemokine 6 Proteins 0.000 description 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 108010083698 Chemokine CCL26 Proteins 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 102000005754 Cytokine Receptor gp130 Human genes 0.000 description 1
- 108010006197 Cytokine Receptor gp130 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Chemical group OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 1
- 102100033167 Elastin Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 101710115997 Gamma-tubulin complex component 2 Proteins 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000713104 Homo sapiens C-C motif chemokine 1 Proteins 0.000 description 1
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 1
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 description 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 1
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 1
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 1
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 1
- 108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 description 1
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 1
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 1
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000049772 Interleukin-16 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 101100462438 Mus musculus Otulin gene Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Chemical group C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102100022396 Nucleosome assembly protein 1-like 4 Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100029837 Probetacellulin Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040825 Skin depigmentation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000003595 dermal dendritic cell Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000000481 effect on pigmentation Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 229940081104 fibrinogen / thrombin Drugs 0.000 description 1
- 239000011724 folic acid Chemical group 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical group [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- RFJIYBACSXLSEQ-UHFFFAOYSA-N monostearoylglycerol Natural products CCCCCCCCCCCCCCCCCOCC(O)CO RFJIYBACSXLSEQ-UHFFFAOYSA-N 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004032 porphyrins Chemical group 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Chemical group 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/985—Skin or skin outgrowth, e.g. hair, nails
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Definitions
- the present invention relates to a composition for treatment or prevention of skin pigmentation, which includes fibroblasts as an active ingredient.
- the skin is an organ that covers the surface of the body, separating the interior of the body from its exterior. Skin functions as a physical barrier and protects the interior of the body from dryness and infiltration of hazardous substances, thus performing an indispensable role for life maintenance.
- the skin of higher vertebrates primarily consists of the epidermis, dermis and subcutaneous tissue layers, in that order from the outermost layer.
- the epidermis is composed mainly of cells known as keratinocytes, the keratinocytes dividing at the deepest part (basal lamina) of the epidermis while migrating to the surface and differentiating toward the upper layer into the stratum spinosum, granular layer and stratum corneum, and eventually being shed as old skin.
- Melanocytes are present in the basal lamina of the epidermis, with melanin being produced by melanosomes inside the melanocytes.
- the melanin that is produced is taken up into the surrounding keratinocytes. After being taken up, the melanin migrates to the stratum corneum with turnover of keratinocytes, being discharged out of the body over a period of about 40 days.
- pigmentation of skin is caused by overproduction of melanin by melanocytes due to hormone imbalance, ultraviolet ray exposure or local inflammation, and by deposition of melanin granules inside keratinocytes in the basal epidermal layer.
- Methods and agents (skin whiteners) for treatment or prevention of pigmentation have been developed, but these have not provided the anticipated effects or have only exhibited temporary effects, resulting in relapse without continual use, and therefore an ongoing demand exists to develop new methods of treatment and prevention, and new therapeutic agents.
- Reference 1 discloses a mixed cell composition comprising melanocytes and fibroblasts to be used for treating skin depigmentation.
- Reference 2 discloses a method of applying autologous skin fibroblasts for anti-aging and particularly for removal of skin wrinkles.
- the present invention encompasses the following inventions.
- composition for treatment or prevention of skin pigmentation containing fibroblasts as an active ingredient, wherein:
- the fibroblasts are fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation, and
- composition is applied to the site of pigmentation or its surrounding dermal tissue.
- composition according to [1] above, wherein the pigmentation is from one or more conditions selected from the group consisting of senile pigmentation spots, seborrheic keratosis, Chloasma, freckles and floriform pigmented spots.
- composition according to [1] or [2] above, wherein the fibroblasts are fibroblasts differentiated from pluripotent stem cells or tissue stem cells.
- composition according to [7] above, wherein the cell senescence marker is one or more selected from the group consisting of senescent acidic ⁇ -galactosidase (SA- ⁇ gal), cell cycle check mechanism-associated factor and cell senescence-associated secretory phenotype (SASP) factor.
- SA- ⁇ gal senescent acidic ⁇ -galactosidase
- SASP cell senescence-associated secretory phenotype
- composition according to any one of [1] to [8] above, which is to be applied by cell therapy.
- a method for treatment or prevention of skin pigmentation which includes application of a composition containing fibroblasts as an active ingredient, to a subject in need thereof, wherein:
- the fibroblasts are fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation, and
- composition is applied to the site of pigmentation or its surrounding dermal tissue.
- a non-therapeutic cosmetic method for reduction or prevention of skin pigmentation which includes application of a composition containing fibroblasts as an active ingredient, to a subject in need thereof, wherein:
- the fibroblasts are fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation, and
- composition is applied to the site of pigmentation or its surrounding dermal tissue.
- the present invention can treat or prevent excess synthesis of melanin at sites of pigmentation.
- FIG. 1 is a schematic diagram showing a method of evaluating a composition of the invention. The constituent elements are shown mainly in cross-sectional form.
- FIG. 2 shows differences in proliferative ability of fibroblasts treated and not treated with PUVA.
- A Image of monolayer cultured fibroblasts either treated with PUVA or not treated (control) (day 1, 4 and 7 of culturing).
- B Proliferation graph of fibroblasts after PUVA treatment.
- FIG. 3 shows differences in senescence-associated factor SA- ⁇ -gal production levels in fibroblasts either treated with PUVA or untreated (control).
- A Enzyme activity values of SA- ⁇ -gal in monolayer cultured fibroblast lysates.
- B SA- ⁇ -gal stained images. The SA- ⁇ -gal positive cells are stained turquoise.
- FIG. 4 shows differences in production levels of the melanin production promoting factor SCF (Stem Cell Factor) in fibroblasts either treated with PUVA or untreated (control).
- SCF melanin production promoting factor
- FIG. 5 shows differences in production levels of the melanin production promoting factor HGF (Hepatocyte Growth Factor) in fibroblasts either treated with PUVA or untreated (control).
- FIG. 6 is a diagram showing pigmentation of a pigmentation skin model either treated or not treated with PUVA.
- A Epidermis model image, for a pigmentation skin model treated with PUVA (day 0 and day 21 of culturing).
- B Epidermis model image, for a pigmentation skin model not treated with PUVA (day 0 and day 21 of culturing).
- FIG. 7 is an image of an epidermis model, prepared by co-culturing an epidermis model for approximately 10 days with a PUVA-treated dermis model, and then transferring onto a PUVA-untreated dermis model and culturing for approximately 10 days.
- FIG. 8 shows pigmentation in a pigmentation skin model either treated with PUVA or not treated (control), and a PUVA-treated pigmentation epidermis model, transferred onto a PUVA-untreated dermis model and cultured (Replace).
- A Image of epidermis model photographed after fixing the observation conditions in the bright field of a phase contrast microscope.
- B Graph showing binarization of image (A), with quantification of the pigmentation area percentage.
- FIG. 9 shows melanin granules in a pigmentation skin model either treated with PUVA or not treated (control), and a PUVA-treated pigmentation epidermis model, transferred onto a PUVA-untreated dermis model and cultured (Replace).
- A Staining of melanin granules in epidermis model slice by Fontana-Masson staining.
- B Graph showing binarization of image (A), with quantification of the melanin granule area percentage.
- FIG. 10 shows activated melanocytes in a pigmentation skin model either treated with PUVA or not treated (control), and a PUVA-treated pigmentation epidermis model, transferred onto a PUVA-untreated dermis model and cultured (Replace).
- A Image of activated melanocytes in epidermis model slice stained using TRP2 (Tyrosine Related Protein 2) antibody, and nuclear-stained by hematoxylin staining.
- B Graph showing quantified percentage of activated melanocytes from image (A).
- first, second and third throughout the present specification are used to distinguish one element from another, and a first element may be referred to as “second element”, or similarly a second element may be referred to as “first element”, without deviating from the gist of the invention.
- the invention provides a composition for treatment or prevention of skin pigmentation containing fibroblasts as an active ingredient, wherein the fibroblasts are fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation, and the composition is applied to the site of pigmentation or its surrounding dermal tissue.
- the present invention allows excessive synthesis of melanin by melanocytes in the epidermis to be reduced, thus helping to treat or prevent skin pigmentation and being useful in cosmetic methods for reduction and prevention of skin pigmentation as well.
- the phrase “dermal tissue surrounding the site of pigmentation” means dermal tissue present at the periphery of the site of pigmentation, such as dermal tissue contained in a region within 1 cm, preferably within 5 mm, more preferably within 3 mm and most preferably within 1 mm from the boundary of the site of pigmentation.
- pigmentation of skin is brought on by overproduction of melanin by melanocytes due to hormone imbalance, ultraviolet ray exposure or local inflammation, and by deposition of melanin granules inside keratinocytes in the basal epidermal layer.
- Pigmentation is caused by conditions such as senile pigmentation spots, seborrheic keratosis, Chloasma, freckles and floriform pigmented spots.
- Fibroblasts are one of the types of cells constituting connective tissue, and they are present in a large number of organs and tissues. Fibroblasts produce constituent components of the dermis, including collagen, elastin and hyaluronic acid.
- the composition of the invention includes fibroblasts having less damage than fibroblasts that are localized at sites of skin pigmentation.
- fibroblasts with less damage than fibroblasts that are localized at the site of skin pigmentation means fibroblasts with less DNA damage than fibroblasts localized at the site of skin pigmentation.
- DNA which carries the genetic information in cells, constantly sustains damage by the effects of active oxygen, ultraviolet rays, radiation and/or chemical substances.
- DNA damage is repaired by the function of various DNA reparation mechanisms in the cell. If the frequency of DNA damage exceeds the rate of DNA repair, however, DNA reparation cannot keep up and DNA damage accumulates. This leads to accumulation of DNA mutations in the cell and an increasing state of senescence of the cell.
- fibroblasts with less damage than fibroblasts that are localized at the site of skin pigmentation can also be considered to be fibroblasts with lower cell senescence than fibroblasts localized at the site of skin pigmentation. It can also be considered to be fibroblasts with smaller cell sizes and/or higher proliferation than fibroblasts localized at the site of skin pigmentation.
- Cell senescence can be evaluated by examining the expression of cell senescence markers.
- cell senescence markers include senescent acidic ⁇ -galactosidase (SA- ⁇ gal), cell cycle check mechanism-related factors (such as p16 INK4a , p21 CIP1 and/or p53), and cell senescence-associated secretory phenotype (SASP) factor, and examining the expression of any one or more of these allows different extents of cell senescence to be compared.
- SA- ⁇ gal senescent acidic ⁇ -galactosidase
- cell cycle check mechanism-related factors such as p16 INK4a , p21 CIP1 and/or p53
- SASP cell senescence-associated secretory phenotype
- SASP factors include, but are not limited to, inflammatory cytokines, chemokines, growth factors and extracellular matrix catabolic enzymes, examples of which include GM-CSF, GRO- ⁇ , GRO- ⁇ , GRO- ⁇ , IGFBP-7, IL-1 ⁇ , IL-6, IL-7, IL-8, MCP-1, MCP-2, MIP-1 ⁇ , MMP-1, MMP-10, MMP-3, amphiregulin, ENA-78, eotaxin-3, GCP-2, GITR, HGF, ICAM-1, IGFBP-2, IGFBP-4, IGFBP-5, IGFBP-6, IL-13, IL-1 ⁇ , MCP-4, MIF, MIP-3 ⁇ , MMP-12, MMP-13, MMP-14, NAP2, oncostatin M, osteoprotegerin, PIGF, RANTES, sgp130, TIMP-2, TRAIL-R3, Acrp30, angiogenin, Axl, bFGF, BLC,
- the method for quantifying a cell senescence marker may be any publicly known method including, but not being limited to, ELISA, real-time PCR, Western blotting, Northern blotting, flow cytometry methods and microarray methods, which are methods allowing different expression levels of cell senescence markers to be compared.
- a composition containing fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation, such as fibroblasts with a lower expression level of a cell senescence marker than fibroblasts localized at the site of pigmentation can be applied to the site of pigmentation or its surrounding dermal tissue to treat or prevent pigmentation.
- fibroblasts used for the invention may be fibroblasts derived from biological tissue with low light exposure or no light exposure.
- biological tissue with low light exposure or no light exposure means a site that is covered by clothes or hair during most of the time period of daily living activities of a human and has relatively low frequency of exposure to light (compared to the face, for example), and examples of such tissues include tissue from the gluteal region, abdominal region, thorax, femoral region, dorsal region, gingiva, oral mucosa, scalp, palm, foot soles and auricle rear regions.
- Fibroblasts derived from tissue with low light exposure are preferred because they have a low frequency of exposure to light, and especially ultraviolet rays, and therefore have a low degree of damage.
- the fibroblasts to be used for the invention may be primary fibroblasts obtained by fine cutting of biological tissue and treatment with proteases such as collagenase or trypsin, or fibroblasts grown by subculturing of the obtained primary human fibroblasts.
- the fibroblasts used for the invention may be ones cultured using a publicly known medium.
- the fibroblasts used for the invention may be autologous fibroblasts.
- Autologous fibroblasts are preferred because they are not rejected by immunoreaction when applied to a subject.
- fibroblasts used for the invention may be fibroblasts differentiated from pluripotent stem cells or tissue stem cells.
- the pluripotent stem cells used may be iPS cells, ES cell or Muse cells, and it is possible to use fibroblasts obtained by inducing differentiation by a publicly known method, or fibroblast progenitor cells (including mesenchymal stem cells, for example) obtained by a differentiation-inducing process.
- tissue is tissue present between the epidermis and subcutaneous tissue of skin, being composed mainly of fibroblasts, collagen, elastic fibers (elastin), extracellular matrix and hyaluronic acid.
- the composition of the invention may be applied to a site of pigmentation or its surrounding dermal tissue to directly or indirectly act on melanocytes within the site of pigmentation and reduce overproduction of melanin.
- the method of applying the composition of the invention may be carried out by any means known in the technical field for providing cell therapy, such as injection of the suspended composition with a syringe.
- composition of the invention may also include a pharmaceutically acceptable carrier in addition to the fibroblasts.
- pharmaceutically acceptable carrier means a diluent, adjuvant, excipient or vehicle that is approved by a domestic regulatory agency and can be used for animals, and particularly humans.
- carriers that may be added to the composition of the invention include, but are not limited to, physiological buffer solutions, injectable gel solutions, physiological saline and water.
- physiological buffer solutions that may be used for the invention include, but are not limited to, buffered saline, phosphate buffered solutions, Hank's balanced salt solution, Tris-buffered saline and HEPES buffered saline.
- An injectable gel solution to be used for the invention may be in the form of a gel before injection, or it may be one that gels after injection.
- An injectable gel solution is composed of water, physiological saline or physiological buffered solution, and a gelling substance, for example.
- gelling substances include, but are not limited to, proteins (such as collagen, elastin, thrombin, fibronectin, gelatin, fibrin, tropoelastin, polypeptides, laminin, proteoglycans, fibrin pastes, self-assembling peptide hydrogels and atelocollagen), polysaccharides (such as pectin, cellulose, oxidized cellulose, chitin, chitosan, agarose and hyaluronic acid), polynucleotides (such as ribonucleic acid and deoxyribonucleic acid), alginates, crosslinked alginates, poly(N-isopropyl acrylamide), poly(oxyalkylene), poly(ethylene oxide)-poly(propylene oxide) copolymer, poly(vinyl alcohol), polyacrylate, monostearoylglycerol cosuccinate/polyethylene glycol (MGSA/PEG) copolymer, and combinations of the foregoing.
- the number of fibroblasts included in the composition of the invention is not restricted since it may be appropriately set depending on the size of the pigmentation to which it is to be applied, the degree of pigmentation, the age of the subject, the condition being treated and the method of application.
- composition of the invention can be evaluated using the pigmentation skin model 1 a shown in FIG. 1 , for example.
- the evaluation can be carried out by a method that includes the following procedure, for example.
- step (2) a step of culturing the fibroblasts 100 obtained in step (1) on a first cell culture insert 11 ( FIG. 1(B) ),
- step (2) (4) a step of setting the second cell culture insert 21 in which the fibroblasts 100 obtained in step (2) have been cultured, onto the fibroblasts 100 obtained in step (2), and culturing them ( FIG. 1(D) ),
- step (6) a step of transferring the second cell culture insert 21 in which the fibroblasts 100 obtained in step (4) have been cultured, onto the third cell culture insert 31 in which the composition 300 obtained in step (5) has been cultured, and culturing them ( FIG. 1(F) ), and
- step (7) a step of evaluating the treatment or prevention effect of the composition 300 , using the extent of pigment production and/or pigmentation in the cell group 200 including the melanocytes 202 and keratinocytes 201 obtained in step (6) as an indicator.
- first cell culture insert 11 in which the fibroblasts 100 have been cultured and the third cell culture insert 31 in which the composition 300 has been cultured may be referred to as “dermis models” (first dermis model 10 and second dermis model 30 ), since they model the structure of the skin dermis.
- second dermis model 30 the structure containing the cell group 200
- epidermis model 20 since it models the structure of the skin epidermis.
- the fibroblasts 100 are preferably photoirradiated in the presence of a photosensitizer to induce damage.
- photosensitizers to be used include psoralen, NAD, riboflavin, tryptophan, folic acid, porphyrin, methylene blue, and thiol group-protected gold nanoclusters (AUxSRy).
- AUxSRy thiol group-protected gold nanoclusters
- the light used to induce damage in the fibroblasts 100 may have a wavelength which causes damage in intracellular nucleic acid such as DNA or RNA but does not result in death of all of the cells, and it is preferably ultraviolet light (about 200 nm to about 400 nm), and more preferably UVA (about 320 nm to about 400 nm).
- the intensity of the irradiated light may be such as to produce damage in the intracellular nucleic acid such as DNA or RNA while not inducing apoptosis and death in all of the cells, and it can be appropriately adjusted by the wavelength or irradiation time, and the cell density.
- Irradiation of UVA may be at 0.01 J/cm 2 to 100 J/cm 2 , preferably 0.1 J/cm 2 to 20 J/cm 2 and more preferably 0.5 J/cm 2 to 10 J/cm 2.
- Fibroblasts that have suffered damage by photoirradiation have elongated cellular forms and reduced proliferation potency, as well as increased production of senescence-associated factors (senescence-associated acidic ⁇ -galactosidase (SA- ⁇ -gal)) and melanin-producing factors (such as stem cell growth factor (SCF) and hepatocyte growth factor (HGF)), and thus an increased level of cell senescence (see FIG. 2 , FIG. 3 , FIG. 4 and FIG. 5 ).
- the level of cell senescence can be evaluated by measuring these cell senescence markers. Adjustment of the photoirradiation dose allows fibroblasts 100 with the desired level of cell senescence to be obtained.
- the second cell culture insert 21 has a smaller inner diameter than the first cell culture insert 11 and third cell culture insert 31 . This will allow the second cell culture insert 21 to be used by insertion into the culture portions of the first cell culture insert 11 and third cell culture insert 31 .
- the cells used in the pigmentation skin model 1 may be derived from any animal, but they are preferably derived from a vertebrate, more preferably from a mammal, and most preferably from a human.
- the fibroblasts 100 used in the pigmentation skin models ( 1 , 1 a ) are preferably fibroblasts derived from the dermis.
- the keratinocytes 201 are a type of cells composing the epidermis, and in biological epidermal tissue they divide at the deepest part (basal lamina) while migrating to the surface and differentiating toward the upper layer into the stratum spinosum, granular layer and stratum corneum, eventually being shed as old skin.
- the melanocytes 202 are a type of cells composing epidermal tissue, which are present in the epidermal basal lamina of biological tissue and produce melanin.
- the fibroblasts 100 , keratinocytes 201 and melanocytes 202 used in the pigmentation skin models ( 1 , 1 a ) may each be primary cultured cells harvested from biological tissue, or cells marketed or distributed after first having been isolated and/or grown, or cells of an established cell line, or cells differentiated from pluripotent stem cells such as ES cells, iPS cells or Muse cells.
- the first dermis model 10 may also contain cells other than fibroblasts 100 , such as mast cells, histiocytes, plasmocytes or dermal dendritic cells that are present within dermal tissue.
- the number of fibroblasts in the first dermis model 10 may be 1 ⁇ 10 4 to 10 8 /cm 2 , and preferably 0.1 to 10 ⁇ 10 5 /cm 2 .
- the first dermis model 10 preferably has the fibroblasts 100 seeded together with a hydrogelling agent.
- hydrogelling agent is a substance added in order to form a hydrogel.
- Hydrogelling agents to be used for the invention may be selected from the group consisting of collagen, gelatin, hyaluronate, hyaluronan, fibrin, alginate, agarose, chitosan, chitin, cellulose, pectin, starch, laminin, fibrinogen/thrombin, fibrillin, elastin, gum, cellulose, agar, gluten, casein, albumin, vitronectin, tenascin, entactin/nidogen, glycoproteins, glycosaminoglycan, poly(acrylic acid) and its derivatives, poly(ethylene oxide) and its copolymers, poly(vinyl alcohol), polyphosphazene, Matrigel, and combinations of the foregoing.
- Step (2) may be carried out in the presence of ascorbic acid or a salt thereof.
- Ascorbic acid or a salt thereof is preferably present in order to promote multilayer formation similar to the structure of the dermis, by accelerated proliferation of the fibroblasts 100 and collagen production.
- “ascorbic acid” refers to ascorbic acid or its derivative (such as ascorbic acid diphosphate, ascorbic acid monophosphate, sodium L-ascorbate and L-ascorbic acid 2-glucoside), as well as its salts (such as sodium salts and magnesium salts).
- the cell group 200 may also include cells other than the keratinocytes 201 and melanocytes 202 , such as Langerhans cells in the epidermal tissue, or Merkel cells.
- the cell group 200 may include the cells in a proportion of keratinocytes 201 :melanocytes 202 of 1:1 to 1000:1 and preferably 30:1 to 3:1.
- the cell group 200 includes the keratinocytes 201 at 1 ⁇ 10 2 to 10 6 /cm 2 , preferably 1.0 to 10 ⁇ 10 4 /cm 2 and more preferably about 4 to 8 ⁇ 10 4 /cm 2 , and the melanocytes 202 at 1 to 10 ⁇ 10 3 /cm 2 and preferably 4 to 8 ⁇ 10 3 /cm 2 .
- the epidermis model 20 may employ TESTSKIN R LSE-melano (TOYOBO) and MelanoDerm R (MatTek), for example, which are commercially available.
- the pigmentation skin model 1 may be cultured using a culture solution commonly used as a culture solution for culturing of keratinocytes, such as KG medium, EpilifeKG2 (Kurabo Industries, Ltd.), Humedia-KG2 (Kurabo Industries, Ltd.) or assay medium (TOYOBO), at about 37° C. for a period of 0 to 30 days.
- the culture medium used may alternatively be DMEM culture medium (Gibco), or a culture medium comprising a 1:1 mixture of ascorbic acid-containing KGM and DMEM.
- the pigmentation skin model 1 has fibroblasts damaged by photoirradiation that has acted directly or indirectly on melanocytes, accelerating melanin production.
- the pigment production and/or extent of pigmentation in the pigmentation skin model 1 can then be measured to evaluate factors that affect pigmentation.
- pigment production refers to production of a pigment such as melanin pigment, which is produced by the pigmentation skin model.
- Melanin pigment is produced primarily by melanocytes.
- the amount of pigment production can be determined as the amount of melanin, by extracting the melanin pigment from the pigmentation skin model, and especially the second cell group (keratinocytes and melanocytes), and measuring the absorbance at 405 nm.
- the amount of pigment production can be measured as the level of melanin or nucleic acid (such as mRNA) coding therefor, present in the pigmentation skin model and particularly the second cell group (keratinocytes and melanocytes), using a method such as ELISA, flow cytometry, Western blotting, an immunohistochemical method or qPCR, with no limitation to these.
- melanin or nucleic acid such as mRNA
- a method such as ELISA, flow cytometry, Western blotting, an immunohistochemical method or qPCR, with no limitation to these.
- “extent of pigmentation” means the color brightness of the pigmentation skin model, and particularly the second cell group (keratinocytes and melanocytes), under visible light.
- the pigmentation skin model of the invention has varying brightness depending on the amount of melanin produced by the melanocytes. A greater amount of melanin results in reduced brightness, so that the pigmentation skin model exhibits a darker color. A lower amount of melanin, conversely, increases the brightness and causes the pigmentation skin model to exhibit a lighter color. That is, the treatment or prevention effect on pigmentation by an added candidate substance can be evaluated by comparing the color brightness of the pigmentation skin model.
- the brightness can be quantified by recording the pigmentation skin model as an image and using publicly known image measuring means.
- Normal human fibroblasts (1 ⁇ 10 5 cells) were cultured with a growth medium (DMEM+10% fetal calf serum). Before reaching 100% confluence, the medium was exchanged with growth medium containing psoralen (final concentration: 25 ng/mL) (Sigma-Aldrich), and culturing was continued.
- DMEM fetal calf serum
- psoralen final concentration: 25 ng/mL
- a dermis model was prepared using fibroblasts subjected to the PUVA treatment of 1-1. above, or without PUVA treatment (control). Briefly, the procedure of 1. above was followed by removal of the growth medium and imbibing with 1 mL PBS. The PBS was then removed, a cell release agent (TrypLE SELECT, Thermo Fisher Scientific) was added at 300 ⁇ L per well of a 6-well plate, and the mixture was allowed to stand for 5 minutes in a 5% CO 2 incubator at 37° C. as cell releasing treatment. Growth medium was added to suspend the reaction, and the cell suspension was recovered in a 15 ml centrifuge tube.
- a cell release agent TrypLE SELECT, Thermo Fisher Scientific
- a gel suspension comprising the composition listed in Table 1 was prepared on ice to prepare a dermis model for application to each well of a 6-well plate.
- a cell culture insert for dermis model preparation was set in the 6-well plate and 3 mL of gel suspension was added into the cell culture insert. After solidifying the gel suspension with a 5% CO 2 incubator at 37° C., 2 mL of growth medium containing ascorbic acid (AA2G) was added to the 6-well plate and culturing was carried out for 24 hours in the 5% CO 2 incubator at 37° C.
- A2G ascorbic acid
- the epidermis model was laid over and combined with the dermis model of 1-2. above (see FIG. 1(D) ) and set in a specialized vessel (Corning BioCoat deep well plate, 6 wells) (Corning #355467), and then 9.5 mL of three-dimensional skin model medium (a 1:1 mixture of epidermis model special medium (MatTek #EPI-100-NMM-113) and DMEM) was added and medium exchange was carried out with the same medium at a frequency of once every 3 to 4 days.
- a specialized vessel Corning BioCoat deep well plate, 6 wells
- DMEM medium exchange was carried out with the same medium at a frequency of once every 3 to 4 days.
- An epidermis model cultured for 10 days in combination with a dermis model prepared using PUVA-treated fibroblasts was replaced with a dermis model prepared using PUVA-untreated normal fibroblasts, and culturing was continued for 10 days (see FIG. 1(E) and (F)).
- the replacement dermis model was prepared on the day prior to replacement.
- FIG. 2 shows PUVA-treated and untreated fibroblasts.
- the PUVA-treated fibroblasts had become elongated ( FIG. 2(A) ).
- FIG. 2(B) Upon examining variation in the number of proliferated PUVA-treated and untreated fibroblasts, it was found that the PUVA-treated fibroblasts had a notably lower growth rate ( FIG. 2(B) ).
- the SCF level of the PUVA-treated fibroblasts was found to be notably higher ( FIG. 4(A) ).
- SCF staining with SCF antibody and nuclear staining with DAPI were carried out and a fused (merged) image for the SCF staining and nuclear stain was created, a large number of SCF-positive cells were observed among the PUVA-treated fibroblasts ( FIG. 4(B) ).
- FIG. 6 is a diagram showing pigmentation in an epidermis model, for a pigmentation skin model either with PUVA treatment (A) or without treatment (B).
- the epidermis model for the PUVA-treated pigmentation skin model showed accelerated pigmentation.
- An epidermis model cultured for 10 days in combination with a dermis model prepared using PUVA-treated fibroblasts was replaced with a dermis model prepared using PUVA-untreated normal fibroblasts, and after culturing for another 10 days, pigmentation was observed to be inhibited ( FIG. 7 ) compared to pigmentation in the epidermis model for the PUVA-treated pigmentation skin model ( FIG. 6(A) ).
- the ratio of the thickest pigmented region in the PUVA-treated pigmentation skin model was high, while the region of thick pigmentation in the pigmentation skin model under the Replace conditions was reduced ( FIG. 8(B) ).
- TRP2 antibody was used for staining of the activated melanocytes in the epidermis model slices, and the nuclei were stained by hematoxylin staining ( FIG. 10(A) ).
Abstract
The present invention provides a composition for treating or preventing skin pigmentation, which contains fibroblasts as an active ingredient, wherein the fibroblasts are those fibroblasts which are less damaged than fibroblasts localized in a site where the skin pigmentation occurs, and the composition is characterized by being intended to be applied to a site where the pigmentation occurs or a dermis tissue around the site.
Description
- The present invention relates to a composition for treatment or prevention of skin pigmentation, which includes fibroblasts as an active ingredient.
- The skin is an organ that covers the surface of the body, separating the interior of the body from its exterior. Skin functions as a physical barrier and protects the interior of the body from dryness and infiltration of hazardous substances, thus performing an indispensable role for life maintenance.
- The skin of higher vertebrates primarily consists of the epidermis, dermis and subcutaneous tissue layers, in that order from the outermost layer. The epidermis is composed mainly of cells known as keratinocytes, the keratinocytes dividing at the deepest part (basal lamina) of the epidermis while migrating to the surface and differentiating toward the upper layer into the stratum spinosum, granular layer and stratum corneum, and eventually being shed as old skin.
- Melanocytes are present in the basal lamina of the epidermis, with melanin being produced by melanosomes inside the melanocytes. The melanin that is produced is taken up into the surrounding keratinocytes. After being taken up, the melanin migrates to the stratum corneum with turnover of keratinocytes, being discharged out of the body over a period of about 40 days.
- It is thought that pigmentation of skin, such as skin spots and freckles, is caused by overproduction of melanin by melanocytes due to hormone imbalance, ultraviolet ray exposure or local inflammation, and by deposition of melanin granules inside keratinocytes in the basal epidermal layer. Methods and agents (skin whiteners) for treatment or prevention of pigmentation such as senile pigmentation spots have been developed, but these have not provided the anticipated effects or have only exhibited temporary effects, resulting in relapse without continual use, and therefore an ongoing demand exists to develop new methods of treatment and prevention, and new therapeutic agents.
- Cellular regenerative medicine has come to be developed in recent years, and it is being applied in the field of cosmetics as well.
Reference 1, for example, discloses a mixed cell composition comprising melanocytes and fibroblasts to be used for treating skin depigmentation.Reference 2 discloses a method of applying autologous skin fibroblasts for anti-aging and particularly for removal of skin wrinkles. -
- [PTL 1] International Patent Publication No. 2007/061168
- [PTL 2] Chinese Patent Application Publication No. 106176561
- It is an object of the invention to provide a composition for treatment or prevention of skin pigmentation.
- As a result of active research by the present inventors, it has been found that skin pigmentation can be treated or prevented if a composition containing fibroblasts with less damage than fibroblasts localized at the site of pigmentation is applied to the surrounding dermal tissue. Specifically, the present invention encompasses the following inventions.
- [1] A composition for treatment or prevention of skin pigmentation, containing fibroblasts as an active ingredient, wherein:
- the fibroblasts are fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation, and
- the composition is applied to the site of pigmentation or its surrounding dermal tissue.
- [2] The composition according to [1] above, wherein the pigmentation is from one or more conditions selected from the group consisting of senile pigmentation spots, seborrheic keratosis, Chloasma, freckles and floriform pigmented spots.
- [3] The composition according to [1] or [2] above, wherein the fibroblasts are derived from biological tissue of a site with low light exposure or no light exposure.
- [4] The composition according to any one of [1] to [3] above, wherein the fibroblasts are derived from a tissue selected from the group consisting of the gluteal region, abdominal region, thorax, femoral region, upper arm, dorsal region, gingiva, oral mucosa, scalp, palms, foot soles and auricle rear.
- [5] The composition according to any one of [1] to [4] above, wherein the fibroblasts are autologous fibroblasts.
- [6] The composition according to [1] or [2] above, wherein the fibroblasts are fibroblasts differentiated from pluripotent stem cells or tissue stem cells. [7] The composition according to any one of [1] to [6] above, wherein the fibroblasts have lower expression of a cell senescence marker than fibroblasts localized at the site of pigmentation.
- [8] The composition according to [7] above, wherein the cell senescence marker is one or more selected from the group consisting of senescent acidic β-galactosidase (SA-βgal), cell cycle check mechanism-associated factor and cell senescence-associated secretory phenotype (SASP) factor.
- [9] The composition according to any one of [1] to [8] above, which is to be applied by cell therapy.
- [10] A method for treatment or prevention of skin pigmentation, which includes application of a composition containing fibroblasts as an active ingredient, to a subject in need thereof, wherein:
- the fibroblasts are fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation, and
- the composition is applied to the site of pigmentation or its surrounding dermal tissue.
- [11] A non-therapeutic cosmetic method for reduction or prevention of skin pigmentation, which includes application of a composition containing fibroblasts as an active ingredient, to a subject in need thereof, wherein:
- the fibroblasts are fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation, and
- the composition is applied to the site of pigmentation or its surrounding dermal tissue.
- The present invention can treat or prevent excess synthesis of melanin at sites of pigmentation.
-
FIG. 1 is a schematic diagram showing a method of evaluating a composition of the invention. The constituent elements are shown mainly in cross-sectional form. -
FIG. 2 shows differences in proliferative ability of fibroblasts treated and not treated with PUVA. (A) Image of monolayer cultured fibroblasts either treated with PUVA or not treated (control) (day -
FIG. 3 shows differences in senescence-associated factor SA-β-gal production levels in fibroblasts either treated with PUVA or untreated (control). (A) Enzyme activity values of SA-β-gal in monolayer cultured fibroblast lysates. (B) SA-β-gal stained images. The SA-β-gal positive cells are stained turquoise. -
FIG. 4 shows differences in production levels of the melanin production promoting factor SCF (Stem Cell Factor) in fibroblasts either treated with PUVA or untreated (control). (A) Graph showing variation in SCF production with time. (B) SCF staining with SCF antibody, nuclear staining with DAPI, and fused (merged) image of SCF staining and nuclear staining (2 each). -
FIG. 5 shows differences in production levels of the melanin production promoting factor HGF (Hepatocyte Growth Factor) in fibroblasts either treated with PUVA or untreated (control). (A) HGF staining with HGF antibody, nuclear staining with DAPI, and fused (merged) image of HGF staining and nuclear staining (2 each). -
FIG. 6 is a diagram showing pigmentation of a pigmentation skin model either treated or not treated with PUVA. (A) Epidermis model image, for a pigmentation skin model treated with PUVA (day 0 andday 21 of culturing). (B) Epidermis model image, for a pigmentation skin model not treated with PUVA (day 0 andday 21 of culturing). -
FIG. 7 is an image of an epidermis model, prepared by co-culturing an epidermis model for approximately 10 days with a PUVA-treated dermis model, and then transferring onto a PUVA-untreated dermis model and culturing for approximately 10 days. -
FIG. 8 shows pigmentation in a pigmentation skin model either treated with PUVA or not treated (control), and a PUVA-treated pigmentation epidermis model, transferred onto a PUVA-untreated dermis model and cultured (Replace). (A) Image of epidermis model photographed after fixing the observation conditions in the bright field of a phase contrast microscope. (B) Graph showing binarization of image (A), with quantification of the pigmentation area percentage. -
FIG. 9 shows melanin granules in a pigmentation skin model either treated with PUVA or not treated (control), and a PUVA-treated pigmentation epidermis model, transferred onto a PUVA-untreated dermis model and cultured (Replace). (A) Staining of melanin granules in epidermis model slice by Fontana-Masson staining. (B) Graph showing binarization of image (A), with quantification of the melanin granule area percentage. -
FIG. 10 shows activated melanocytes in a pigmentation skin model either treated with PUVA or not treated (control), and a PUVA-treated pigmentation epidermis model, transferred onto a PUVA-untreated dermis model and cultured (Replace). (A) Image of activated melanocytes in epidermis model slice stained using TRP2 (Tyrosine Related Protein 2) antibody, and nuclear-stained by hematoxylin staining. (B) Graph showing quantified percentage of activated melanocytes from image (A). - Embodiments for carrying out the invention will be described in detail below with reference to the accompanying drawings, with the understanding that the technical scope of the invention is not limited only to these embodiments.
- The terms “first, “second” and “third” throughout the present specification are used to distinguish one element from another, and a first element may be referred to as “second element”, or similarly a second element may be referred to as “first element”, without deviating from the gist of the invention.
- Unless otherwise defined, the terms (technical and scientific terms) used herein have the same meanings as generally understood by those skilled in the art.
- According to one embodiment, the invention provides a composition for treatment or prevention of skin pigmentation containing fibroblasts as an active ingredient, wherein the fibroblasts are fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation, and the composition is applied to the site of pigmentation or its surrounding dermal tissue. The present invention allows excessive synthesis of melanin by melanocytes in the epidermis to be reduced, thus helping to treat or prevent skin pigmentation and being useful in cosmetic methods for reduction and prevention of skin pigmentation as well. Throughout the present specification, the phrase “dermal tissue surrounding the site of pigmentation” means dermal tissue present at the periphery of the site of pigmentation, such as dermal tissue contained in a region within 1 cm, preferably within 5 mm, more preferably within 3 mm and most preferably within 1 mm from the boundary of the site of pigmentation.
- It is thought that pigmentation of skin, such as skin spots and freckles, is brought on by overproduction of melanin by melanocytes due to hormone imbalance, ultraviolet ray exposure or local inflammation, and by deposition of melanin granules inside keratinocytes in the basal epidermal layer. Pigmentation is caused by conditions such as senile pigmentation spots, seborrheic keratosis, Chloasma, freckles and floriform pigmented spots. By applying the present invention, therefore, it is possible to reduce excess synthesis of melanin by melanocytes at sites of pigmentation, thus helping to treat or prevent skin pigmentation and being useful in cosmetic methods for reduction and prevention of skin pigmentation as well.
- Fibroblasts are one of the types of cells constituting connective tissue, and they are present in a large number of organs and tissues. Fibroblasts produce constituent components of the dermis, including collagen, elastin and hyaluronic acid. The composition of the invention includes fibroblasts having less damage than fibroblasts that are localized at sites of skin pigmentation. The phrase “fibroblasts with less damage than fibroblasts that are localized at the site of skin pigmentation”, as used herein, means fibroblasts with less DNA damage than fibroblasts localized at the site of skin pigmentation. DNA, which carries the genetic information in cells, constantly sustains damage by the effects of active oxygen, ultraviolet rays, radiation and/or chemical substances. Such DNA damage is repaired by the function of various DNA reparation mechanisms in the cell. If the frequency of DNA damage exceeds the rate of DNA repair, however, DNA reparation cannot keep up and DNA damage accumulates. This leads to accumulation of DNA mutations in the cell and an increasing state of senescence of the cell.
- The phrase “fibroblasts with less damage than fibroblasts that are localized at the site of skin pigmentation” can also be considered to be fibroblasts with lower cell senescence than fibroblasts localized at the site of skin pigmentation. It can also be considered to be fibroblasts with smaller cell sizes and/or higher proliferation than fibroblasts localized at the site of skin pigmentation. Cell senescence can be evaluated by examining the expression of cell senescence markers. Examples of known cell senescence markers include senescent acidic β-galactosidase (SA-βgal), cell cycle check mechanism-related factors (such as p16INK4a, p21CIP1 and/or p53), and cell senescence-associated secretory phenotype (SASP) factor, and examining the expression of any one or more of these allows different extents of cell senescence to be compared.
- SASP factors include, but are not limited to, inflammatory cytokines, chemokines, growth factors and extracellular matrix catabolic enzymes, examples of which include GM-CSF, GRO-α, GRO-β, GRO-γ, IGFBP-7, IL-1α, IL-6, IL-7, IL-8, MCP-1, MCP-2, MIP-1α, MMP-1, MMP-10, MMP-3, amphiregulin, ENA-78, eotaxin-3, GCP-2, GITR, HGF, ICAM-1, IGFBP-2, IGFBP-4, IGFBP-5, IGFBP-6, IL-13, IL-1β, MCP-4, MIF, MIP-3α, MMP-12, MMP-13, MMP-14, NAP2, oncostatin M, osteoprotegerin, PIGF, RANTES, sgp130, TIMP-2, TRAIL-R3, Acrp30, angiogenin, Axl, bFGF, BLC, BTC, CTACK, EGF-R, Fas, FGF-7, G-CSF, GDNF, HCC-4, I-309, IFN-γ, IGFBP-1, IGFBP-3, IL-1 R1, IL-11, IL-15, IL-2R-α, IL-6R, I-TAC, leptin, LIF, MMP-2, MSP-a, PAI-1, PAI-2, PDGF-BB, SCF, SDF-1, sTNF RI, sTNF RII, thrombopoietin, TIMP-1, tPA, uPA, uPAR, VEGF, MCP-3, IGF-1, TGF-β, MIP-1-delta, IL-4, FGF-7, PDGF-BB, IL-16, BMP-4, MDC, MCP-4, IL-10, TIMP-1, Fit-3 ligand, ICAM-1, Axl, CNTF, INF-γ, EGF and BMP-6. Different degrees of cell senescence can be compared by examining expression levels of one or more of these factors.
- The method for quantifying a cell senescence marker may be any publicly known method including, but not being limited to, ELISA, real-time PCR, Western blotting, Northern blotting, flow cytometry methods and microarray methods, which are methods allowing different expression levels of cell senescence markers to be compared. A composition containing fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation, such as fibroblasts with a lower expression level of a cell senescence marker than fibroblasts localized at the site of pigmentation, can be applied to the site of pigmentation or its surrounding dermal tissue to treat or prevent pigmentation.
- According to one embodiment, fibroblasts used for the invention may be fibroblasts derived from biological tissue with low light exposure or no light exposure. The phrase “biological tissue with low light exposure or no light exposure”, as used herein, means a site that is covered by clothes or hair during most of the time period of daily living activities of a human and has relatively low frequency of exposure to light (compared to the face, for example), and examples of such tissues include tissue from the gluteal region, abdominal region, thorax, femoral region, dorsal region, gingiva, oral mucosa, scalp, palm, foot soles and auricle rear regions. Fibroblasts derived from tissue with low light exposure are preferred because they have a low frequency of exposure to light, and especially ultraviolet rays, and therefore have a low degree of damage. According to one embodiment, the fibroblasts to be used for the invention may be primary fibroblasts obtained by fine cutting of biological tissue and treatment with proteases such as collagenase or trypsin, or fibroblasts grown by subculturing of the obtained primary human fibroblasts. According to one embodiment, the fibroblasts used for the invention may be ones cultured using a publicly known medium.
- According to another embodiment, the fibroblasts used for the invention may be autologous fibroblasts. Autologous fibroblasts are preferred because they are not rejected by immunoreaction when applied to a subject.
- According to another embodiment, fibroblasts used for the invention may be fibroblasts differentiated from pluripotent stem cells or tissue stem cells. The pluripotent stem cells used may be iPS cells, ES cell or Muse cells, and it is possible to use fibroblasts obtained by inducing differentiation by a publicly known method, or fibroblast progenitor cells (including mesenchymal stem cells, for example) obtained by a differentiation-inducing process.
- Throughout the present specification, “dermal tissue (or dermis)” is tissue present between the epidermis and subcutaneous tissue of skin, being composed mainly of fibroblasts, collagen, elastic fibers (elastin), extracellular matrix and hyaluronic acid. The composition of the invention may be applied to a site of pigmentation or its surrounding dermal tissue to directly or indirectly act on melanocytes within the site of pigmentation and reduce overproduction of melanin. The method of applying the composition of the invention may be carried out by any means known in the technical field for providing cell therapy, such as injection of the suspended composition with a syringe.
- The composition of the invention may also include a pharmaceutically acceptable carrier in addition to the fibroblasts. As used herein, “pharmaceutically acceptable carrier” means a diluent, adjuvant, excipient or vehicle that is approved by a domestic regulatory agency and can be used for animals, and particularly humans. According to one embodiment, carriers that may be added to the composition of the invention include, but are not limited to, physiological buffer solutions, injectable gel solutions, physiological saline and water. Examples of physiological buffer solutions that may be used for the invention include, but are not limited to, buffered saline, phosphate buffered solutions, Hank's balanced salt solution, Tris-buffered saline and HEPES buffered saline.
- An injectable gel solution to be used for the invention may be in the form of a gel before injection, or it may be one that gels after injection. An injectable gel solution is composed of water, physiological saline or physiological buffered solution, and a gelling substance, for example. Examples of gelling substances include, but are not limited to, proteins (such as collagen, elastin, thrombin, fibronectin, gelatin, fibrin, tropoelastin, polypeptides, laminin, proteoglycans, fibrin pastes, self-assembling peptide hydrogels and atelocollagen), polysaccharides (such as pectin, cellulose, oxidized cellulose, chitin, chitosan, agarose and hyaluronic acid), polynucleotides (such as ribonucleic acid and deoxyribonucleic acid), alginates, crosslinked alginates, poly(N-isopropyl acrylamide), poly(oxyalkylene), poly(ethylene oxide)-poly(propylene oxide) copolymer, poly(vinyl alcohol), polyacrylate, monostearoylglycerol cosuccinate/polyethylene glycol (MGSA/PEG) copolymer, and combinations of the foregoing.
- The number of fibroblasts included in the composition of the invention is not restricted since it may be appropriately set depending on the size of the pigmentation to which it is to be applied, the degree of pigmentation, the age of the subject, the condition being treated and the method of application.
- The composition of the invention can be evaluated using the
pigmentation skin model 1 a shown inFIG. 1 , for example. The evaluation can be carried out by a method that includes the following procedure, for example. - (1) A step of damaging
fibroblasts 100 with photoirradiation and then culturing them (FIG. 1(A) ), - (2) a step of culturing the
fibroblasts 100 obtained in step (1) on a first cell culture insert 11 (FIG. 1(B) ), - (3) a step of culturing a
cell group 200 including melanocytes 202 and keratinocytes 201 on a second cell culture insert 21 (FIG. 1(C) ), - (4) a step of setting the second
cell culture insert 21 in which thefibroblasts 100 obtained in step (2) have been cultured, onto thefibroblasts 100 obtained in step (2), and culturing them (FIG. 1(D) ), - (5) a step of culturing a composition 300 on a third cell culture insert 31 (
FIG. 1(E) ), - (6) a step of transferring the second
cell culture insert 21 in which thefibroblasts 100 obtained in step (4) have been cultured, onto the third cell culture insert 31 in which the composition 300 obtained in step (5) has been cultured, and culturing them (FIG. 1(F) ), and - (7) a step of evaluating the treatment or prevention effect of the composition 300, using the extent of pigment production and/or pigmentation in the
cell group 200 including the melanocytes 202 and keratinocytes 201 obtained in step (6) as an indicator. - Throughout the present specification, the first
cell culture insert 11 in which thefibroblasts 100 have been cultured and the third cell culture insert 31 in which the composition 300 has been cultured may be referred to as “dermis models” (first dermis model 10 and second dermis model 30), since they model the structure of the skin dermis. Also throughout the present specification, the structure containing thecell group 200 may be referred to as “epidermis model 20” since it models the structure of the skin epidermis. - The
fibroblasts 100 are preferably photoirradiated in the presence of a photosensitizer to induce damage. Examples of photosensitizers to be used include psoralen, NAD, riboflavin, tryptophan, folic acid, porphyrin, methylene blue, and thiol group-protected gold nanoclusters (AUxSRy). By using a photosensitizer it is possible to cause sensitization to the irradiated light and more efficiently induce damage in thefibroblasts 100. - The light used to induce damage in the
fibroblasts 100 may have a wavelength which causes damage in intracellular nucleic acid such as DNA or RNA but does not result in death of all of the cells, and it is preferably ultraviolet light (about 200 nm to about 400 nm), and more preferably UVA (about 320 nm to about 400 nm). The intensity of the irradiated light may be such as to produce damage in the intracellular nucleic acid such as DNA or RNA while not inducing apoptosis and death in all of the cells, and it can be appropriately adjusted by the wavelength or irradiation time, and the cell density. Irradiation of UVA, for example, may be at 0.01 J/cm2 to 100 J/cm2, preferably 0.1 J/cm2 to 20 J/cm2 and more preferably 0.5 J/cm2 to 10 J/cm2. - If the photoirradiated fibroblasts are cultured for a fixed time period it is possible to cause proliferation of only the surviving
fibroblasts 100 that have not undergone apoptosis (FIG. 1(A) ). Fibroblasts that have suffered damage by photoirradiation have elongated cellular forms and reduced proliferation potency, as well as increased production of senescence-associated factors (senescence-associated acidic β-galactosidase (SA-β-gal)) and melanin-producing factors (such as stem cell growth factor (SCF) and hepatocyte growth factor (HGF)), and thus an increased level of cell senescence (seeFIG. 2 ,FIG. 3 ,FIG. 4 andFIG. 5 ). The level of cell senescence can be evaluated by measuring these cell senescence markers. Adjustment of the photoirradiation dose allowsfibroblasts 100 with the desired level of cell senescence to be obtained. - The second
cell culture insert 21 has a smaller inner diameter than the firstcell culture insert 11 and third cell culture insert 31. This will allow the secondcell culture insert 21 to be used by insertion into the culture portions of the firstcell culture insert 11 and third cell culture insert 31. - The cells used in the
pigmentation skin model 1 may be derived from any animal, but they are preferably derived from a vertebrate, more preferably from a mammal, and most preferably from a human. - The
fibroblasts 100 used in the pigmentation skin models (1, 1 a) are preferably fibroblasts derived from the dermis. - The keratinocytes 201 are a type of cells composing the epidermis, and in biological epidermal tissue they divide at the deepest part (basal lamina) while migrating to the surface and differentiating toward the upper layer into the stratum spinosum, granular layer and stratum corneum, eventually being shed as old skin.
- The melanocytes 202 are a type of cells composing epidermal tissue, which are present in the epidermal basal lamina of biological tissue and produce melanin.
- The
fibroblasts 100, keratinocytes 201 and melanocytes 202 used in the pigmentation skin models (1, 1 a) may each be primary cultured cells harvested from biological tissue, or cells marketed or distributed after first having been isolated and/or grown, or cells of an established cell line, or cells differentiated from pluripotent stem cells such as ES cells, iPS cells or Muse cells. - The
first dermis model 10 may also contain cells other thanfibroblasts 100, such as mast cells, histiocytes, plasmocytes or dermal dendritic cells that are present within dermal tissue. The number of fibroblasts in thefirst dermis model 10 may be 1×104 to 108/cm2, and preferably 0.1 to 10×105/cm2. - The
first dermis model 10 preferably has thefibroblasts 100 seeded together with a hydrogelling agent. As used herein, “hydrogelling agent” is a substance added in order to form a hydrogel. Hydrogelling agents to be used for the invention may be selected from the group consisting of collagen, gelatin, hyaluronate, hyaluronan, fibrin, alginate, agarose, chitosan, chitin, cellulose, pectin, starch, laminin, fibrinogen/thrombin, fibrillin, elastin, gum, cellulose, agar, gluten, casein, albumin, vitronectin, tenascin, entactin/nidogen, glycoproteins, glycosaminoglycan, poly(acrylic acid) and its derivatives, poly(ethylene oxide) and its copolymers, poly(vinyl alcohol), polyphosphazene, Matrigel, and combinations of the foregoing. - Step (2) may be carried out in the presence of ascorbic acid or a salt thereof. Ascorbic acid or a salt thereof is preferably present in order to promote multilayer formation similar to the structure of the dermis, by accelerated proliferation of the
fibroblasts 100 and collagen production. Throughout the present specification, “ascorbic acid” refers to ascorbic acid or its derivative (such as ascorbic acid diphosphate, ascorbic acid monophosphate, sodium L-ascorbate and L-ascorbic acid 2-glucoside), as well as its salts (such as sodium salts and magnesium salts). - The
cell group 200 may also include cells other than the keratinocytes 201 and melanocytes 202, such as Langerhans cells in the epidermal tissue, or Merkel cells. Thecell group 200 may include the cells in a proportion of keratinocytes 201:melanocytes 202 of 1:1 to 1000:1 and preferably 30:1 to 3:1. Thecell group 200 includes the keratinocytes 201 at 1×102 to 106/cm2, preferably 1.0 to 10×104/cm2 and more preferably about 4 to 8×104/cm2, and the melanocytes 202 at 1 to 10×103/cm2 and preferably 4 to 8×103/cm2. - The
epidermis model 20 may employ TESTSKINR LSE-melano (TOYOBO) and MelanoDermR (MatTek), for example, which are commercially available. - The
pigmentation skin model 1 may be cultured using a culture solution commonly used as a culture solution for culturing of keratinocytes, such as KG medium, EpilifeKG2 (Kurabo Industries, Ltd.), Humedia-KG2 (Kurabo Industries, Ltd.) or assay medium (TOYOBO), at about 37° C. for a period of 0 to 30 days. The culture medium used may alternatively be DMEM culture medium (Gibco), or a culture medium comprising a 1:1 mixture of ascorbic acid-containing KGM and DMEM. - The
pigmentation skin model 1 has fibroblasts damaged by photoirradiation that has acted directly or indirectly on melanocytes, accelerating melanin production. The pigment production and/or extent of pigmentation in thepigmentation skin model 1 can then be measured to evaluate factors that affect pigmentation. - As used herein, “pigment production” refers to production of a pigment such as melanin pigment, which is produced by the pigmentation skin model. Melanin pigment is produced primarily by melanocytes. The amount of pigment production can be determined as the amount of melanin, by extracting the melanin pigment from the pigmentation skin model, and especially the second cell group (keratinocytes and melanocytes), and measuring the absorbance at 405 nm. The amount of pigment production can be measured as the level of melanin or nucleic acid (such as mRNA) coding therefor, present in the pigmentation skin model and particularly the second cell group (keratinocytes and melanocytes), using a method such as ELISA, flow cytometry, Western blotting, an immunohistochemical method or qPCR, with no limitation to these.
- As used herein, “extent of pigmentation” means the color brightness of the pigmentation skin model, and particularly the second cell group (keratinocytes and melanocytes), under visible light. The pigmentation skin model of the invention has varying brightness depending on the amount of melanin produced by the melanocytes. A greater amount of melanin results in reduced brightness, so that the pigmentation skin model exhibits a darker color. A lower amount of melanin, conversely, increases the brightness and causes the pigmentation skin model to exhibit a lighter color. That is, the treatment or prevention effect on pigmentation by an added candidate substance can be evaluated by comparing the color brightness of the pigmentation skin model. The brightness can be quantified by recording the pigmentation skin model as an image and using publicly known image measuring means.
- The present invention will now be explained in greater detail by examples, with the understanding that the invention is not limited in any way by the examples.
- Normal human fibroblasts (1×105 cells) were cultured with a growth medium (DMEM+10% fetal calf serum). Before reaching 100% confluence, the medium was exchanged with growth medium containing psoralen (final concentration: 25 ng/mL) (Sigma-Aldrich), and culturing was continued. After 24 hours, the cells were imbibed with 1 mL phosphate-buffered saline (PBS), the PBS was removed, the medium was exchanged with 1 mL PBS containing psoralen (final concentration: 25 ng/mL), and UVA irradiation (SAN-EI UVE-502S) was carried out at 6 J/cm2 (hereunder this will be referred to as “PUVA treatment”). This was followed by imbibing with 1 mL PBS and then removal of the PBS, exchange with growth medium, and continued culturing for about 2 to 7 days. Some of the cells died by the effects of PUVA treatment during the procedure, with the surviving fibroblasts continuing to proliferate. Fibroblasts from the same donor without PUVA treatment were used as a control in comparison with the PUVA-treated fibroblasts (
FIGS. 2 to 5 ). - A dermis model was prepared using fibroblasts subjected to the PUVA treatment of 1-1. above, or without PUVA treatment (control). Briefly, the procedure of 1. above was followed by removal of the growth medium and imbibing with 1 mL PBS. The PBS was then removed, a cell release agent (TrypLE SELECT, Thermo Fisher Scientific) was added at 300 μL per well of a 6-well plate, and the mixture was allowed to stand for 5 minutes in a 5% CO2 incubator at 37° C. as cell releasing treatment. Growth medium was added to suspend the reaction, and the cell suspension was recovered in a 15 ml centrifuge tube. After centrifugation at 1000 rpm for 5 minutes, the supernatant was removed and the cell pellet was resuspended in growth medium and adjusted to 5×105 cells/mL. A gel suspension comprising the composition listed in Table 1 was prepared on ice to prepare a dermis model for application to each well of a 6-well plate.
-
TABLE 1 Composition of gel suspension for dermis model containing fibroblasts Reagent Amount Pig skin collagen (final concentration: 0.5% (w/v)) 1.5 mL (NH Foods Ltd., 309-31595) 5 × DMEM 0.6 mL Fetal bovine serum (final concentration: 10% (v/v)) 0.3 mL L-ascorbic acid 2-glucoside(AA2G) (final concentration: 3 μL 250 μM) (Sigma-Aldrich, SMB00390) Fibroblast suspension 0.6 mL Total volume 3 mL - A cell culture insert for dermis model preparation was set in the 6-well plate and 3 mL of gel suspension was added into the cell culture insert. After solidifying the gel suspension with a 5% CO2 incubator at 37° C., 2 mL of growth medium containing ascorbic acid (AA2G) was added to the 6-well plate and culturing was carried out for 24 hours in the 5% CO2 incubator at 37° C.
- 1-3. Pigmentation Skin Model Combined with Epidermis Model
- Separately from the dermis model, a commercially available epidermis model (MatTek Co.) comprising melanocytes and keratinocytes was also used (see
FIG. 1(C) ). - The epidermis model was laid over and combined with the dermis model of 1-2. above (see
FIG. 1(D) ) and set in a specialized vessel (Corning BioCoat deep well plate, 6 wells) (Corning #355467), and then 9.5 mL of three-dimensional skin model medium (a 1:1 mixture of epidermis model special medium (MatTek #EPI-100-NMM-113) and DMEM) was added and medium exchange was carried out with the same medium at a frequency of once every 3 to 4 days. - 1-4. Pigmentation Skin Model with Replaced Dermis Model
- An epidermis model cultured for 10 days in combination with a dermis model prepared using PUVA-treated fibroblasts was replaced with a dermis model prepared using PUVA-untreated normal fibroblasts, and culturing was continued for 10 days (see
FIG. 1(E) and (F)). The replacement dermis model (dermis model prepared using PUVA-untreated fibroblasts) was prepared on the day prior to replacement. -
FIG. 2 shows PUVA-treated and untreated fibroblasts. The PUVA-treated fibroblasts had become elongated (FIG. 2(A) ). Upon examining variation in the number of proliferated PUVA-treated and untreated fibroblasts, it was found that the PUVA-treated fibroblasts had a notably lower growth rate (FIG. 2(B) ). - Upon examining the enzyme activity values of senescence-associated factor SA-β-gal in cell lysates of PUVA-treated and untreated fibroblasts, it was found that the PUVA-treated fibroblasts had notably increased SA-β-gal enzyme activity (
FIG. 3(A) ). With SA-β-gal staining, the PUVA-treated fibroblasts were observed to have a very large number of SA-β-gal positive cells (turquoise) (FIG. 3(B) ). - When the PUVA-treated and untreated fibroblasts were each cultured by monolayer culture, with measurement of the SCF amounts in the
culture supernatants 1 day before PUVA treatment and 0, 1, 3, 7, 14 and 21 days after PUVA treatment by ELISA, and calculation of the amount of secretion per cell, the SCF level of the PUVA-treated fibroblasts was found to be notably higher (FIG. 4(A) ). When SCF staining with SCF antibody and nuclear staining with DAPI were carried out and a fused (merged) image for the SCF staining and nuclear stain was created, a large number of SCF-positive cells were observed among the PUVA-treated fibroblasts (FIG. 4(B) ). - When PUVA-treated and untreated fibroblasts were each cultured by monolayer culture, and then HGF staining with HGF antibody and nuclear staining with DAPI were carried out and a fused (merged) image for the HGF staining and nuclear stain was created, a large number of HGF-positive cells were observed among the PUVA-treated fibroblasts (
FIG. 5(A) ). -
FIG. 6 is a diagram showing pigmentation in an epidermis model, for a pigmentation skin model either with PUVA treatment (A) or without treatment (B). The epidermis model for the PUVA-treated pigmentation skin model showed accelerated pigmentation. - 2-6. Pigmentation Skin Model with Replaced Dermis Model
- An epidermis model cultured for 10 days in combination with a dermis model prepared using PUVA-treated fibroblasts was replaced with a dermis model prepared using PUVA-untreated normal fibroblasts, and after culturing for another 10 days, pigmentation was observed to be inhibited (
FIG. 7 ) compared to pigmentation in the epidermis model for the PUVA-treated pigmentation skin model (FIG. 6(A) ). - 2-7. Pigmentation in Pigmentation Skin Models with PUVA Treatment, without Treatment, and with Dermis Model Replacement
- A PUVA-treated or untreated (control) pigmentation skin model, and an epidermis model which was an epidermis model of a PUVA-treated pigmentation skin model transferred onto a PUVA-untreated dermis model and cultured (Replace), were outwardly observed, and as a result the pigmentation in the epidermis model of the PUVA-treated pigmentation skin model was found to be accelerated while pigmentation in the epidermis model under the Replace conditions was alleviated (
FIG. 8(A) ). Upon quantification based on the image ofFIG. 8(A) , the ratio of the thickest pigmented region in the PUVA-treated pigmentation skin model was high, while the region of thick pigmentation in the pigmentation skin model under the Replace conditions was reduced (FIG. 8(B) ). - 2-8. Melanin Formation in Pigmentation Skin Model with PUVA Treatment, without Treatment, and with Dermis Model Replacement
- After preparing slices of a PUVA-treated or untreated (control) pigmentation skin model, and an epidermis model which was a PUVA-treated pigmentation skin model replaced on a PUVA-untreated dermis model and cultured (Replace), the melanin granules in the epidermis model slices were stained by Fontana-Masson staining (
FIG. 9(A) ). When the stained image ofFIG. 9(A) was binarized and the ratio of melanin granule regions was quantified, it was found that the ratio of melanin regions was highest in the PUVA-treated pigmentation skin model, while the melanin regions in the pigmentation skin model under the Replace conditions were reduced (FIG. 9(B) ). - 2-9. Number of Melanocytes in Pigmentation Skin Model with PUVA Treatment, without Treatment, and with Dermis Model Replacement
- After preparing slices of a PUVA-treated or untreated (control) pigmentation skin model, and an epidermis model which was a PUVA-treated pigmentation skin model replaced on a PUVA-untreated dermis model and cultured (Replace), TRP2 antibody was used for staining of the activated melanocytes in the epidermis model slices, and the nuclei were stained by hematoxylin staining (
FIG. 10(A) ). When the ratio of activated melanocytes was quantified from the image ofFIG. 10(A) , it was found that the ratio of activated melanocytes was highest in the PUVA-treated pigmentation skin model, while the number of activated melanocytes in the pigmentation skin model under the Replace conditions was reduced (FIG. 10(B) ). -
- 1, 1 a Pigmentation skin model
- 10 First dermis model
- 100 Fibroblasts
- 11 First cell culture insert
- 12 First cell culturing vessel
- 13 First medium
- 14 Second medium
- 20 Epidermis model
- 200 Cell group containing melanocytes and keratinocytes
- 201 Keratinocytes
- 202 Melanocytes
- 21 Second cell culture insert
- 22 Second cell culturing vessel
- 23 Third medium
- 24 Fourth medium
- 30 Second dermis model
- 300 Composition
- 31 Third cell culture insert
- 32 Third cell culturing vessel
- RD Photoirradiation
- dFB Fibroblasts damaged by photoirradiation
Claims (9)
1. A composition for treatment or prevention of skin pigmentation, containing fibroblasts as an active ingredient, wherein:
the fibroblasts are fibroblasts with less damage than fibroblasts localized at the site of skin pigmentation, and
the composition is applied to the site of pigmentation or its surrounding dermal tissue.
2. The composition according to claim 1 , wherein the pigmentation is from one or more conditions selected from the group consisting of senile pigmentation spots, seborrheic keratosis, Chloasma, freckles and floriform pigmented spots.
3. The composition according to claim 1 , wherein the fibroblasts are derived from biological tissue of a site with low light exposure or no light exposure.
4. The composition according to claim 1 , wherein the fibroblasts are derived from a tissue selected from the group consisting of the gluteal region, abdominal region, thorax, femoral region, upper arm, dorsal region, gingiva, oral mucosa, scalp, palms, foot soles and auricle rear.
5. The composition according to claim 1 , wherein the fibroblasts are autologous fibroblasts.
6. The composition according to claim 1 , wherein the fibroblasts are fibroblasts differentiated from pluripotent stem cells or tissue stem cells.
7. The composition according to claim 1 , wherein the fibroblasts have lower expression of a cell senescence marker than fibroblasts localized at the site of skin pigmentation.
8. The composition according to claim 7 , wherein the cell senescence marker is one or more selected from the group consisting of senescent acidic β-galactosidase (SA-βgal), cell cycle check mechanism-associated factor and cell senescence-associated secretory phenotype (SASP) factor.
9. The composition according to claim 1 , which is to be applied by cell therapy.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018-226032 | 2018-11-30 | ||
JP2018226032 | 2018-11-30 | ||
PCT/JP2019/046903 WO2020111271A1 (en) | 2018-11-30 | 2019-11-29 | Composition for treating or preventing skin pigmentation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/046903 A-371-Of-International WO2020111271A1 (en) | 2018-11-30 | 2019-11-29 | Composition for treating or preventing skin pigmentation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/225,377 Division US20230364006A1 (en) | 2018-11-30 | 2023-07-24 | Composition for treating or preventing skin pigmentation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220023197A1 true US20220023197A1 (en) | 2022-01-27 |
Family
ID=70853258
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/298,440 Abandoned US20220023197A1 (en) | 2018-11-30 | 2019-11-29 | Composition for treating or preventing skin pigmentation |
US18/225,377 Pending US20230364006A1 (en) | 2018-11-30 | 2023-07-24 | Composition for treating or preventing skin pigmentation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/225,377 Pending US20230364006A1 (en) | 2018-11-30 | 2023-07-24 | Composition for treating or preventing skin pigmentation |
Country Status (8)
Country | Link |
---|---|
US (2) | US20220023197A1 (en) |
EP (1) | EP3888756A4 (en) |
JP (1) | JPWO2020111271A1 (en) |
KR (1) | KR20210097117A (en) |
CN (1) | CN113164783A (en) |
SG (1) | SG11202105105SA (en) |
TW (1) | TW202038976A (en) |
WO (1) | WO2020111271A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160206551A1 (en) * | 2015-01-15 | 2016-07-21 | William K. Boss, Jr. | Methods for the repair and rejuvenation of tissues using platelet-rich plasma compositions |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030091665A1 (en) * | 2001-11-09 | 2003-05-15 | Avon Products, Inc | Topical cosmetic composition with skin rejuvenation benefits |
FR2872431B1 (en) * | 2004-07-02 | 2007-07-20 | Univ Rene Descartes Paris V Et | USE OF GINGIVAL FIBROPLASES IN VASCULAR CELL THERAPY |
JP2007061168A (en) | 2005-08-29 | 2007-03-15 | Shin Taiyo:Kk | Inner rail attaching structure of pachinko game machine |
KR100806695B1 (en) | 2005-11-25 | 2008-02-27 | 주식회사 엠씨티티 | Pharmaceutical Compositions for Cell Therapy of Pigmentation Disorders |
WO2007091409A1 (en) * | 2006-02-08 | 2007-08-16 | Keio University | Feeder cell derived from tissue stem cell |
WO2008136183A1 (en) * | 2007-04-28 | 2008-11-13 | Applied Cell Biotechnologies, Inc. | Composition for repairing defect in skin or gingival soft tissue and method of culturing autologous fibroblasts |
CA2658074C (en) * | 2008-03-17 | 2017-11-07 | L'oreal | Functional pigmented skin equivalent |
JP6244594B2 (en) * | 2013-03-12 | 2017-12-13 | 株式会社東洋新薬 | Aging inhibitor |
RU2568059C1 (en) * | 2014-11-11 | 2015-11-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной генетики Российской академии наук (ИМГ РАН) | Method of obtaining of patient (donor) - specific fibroblast-like cells from induced pluripotent human stem cells |
WO2016114781A1 (en) * | 2015-01-15 | 2016-07-21 | Boss William K Jr | Repair and rejuvenation of tissues using platelet-rich plasma |
CN106176561A (en) | 2016-07-19 | 2016-12-07 | 安徽惠恩生物科技股份有限公司 | A kind of autologous skin fibroblast is for the preparation method of beautifying and antisenility |
-
2019
- 2019-11-29 TW TW108143694A patent/TW202038976A/en unknown
- 2019-11-29 WO PCT/JP2019/046903 patent/WO2020111271A1/en active Application Filing
- 2019-11-29 CN CN201980078342.6A patent/CN113164783A/en active Pending
- 2019-11-29 US US17/298,440 patent/US20220023197A1/en not_active Abandoned
- 2019-11-29 SG SG11202105105SA patent/SG11202105105SA/en unknown
- 2019-11-29 EP EP19889388.5A patent/EP3888756A4/en active Pending
- 2019-11-29 KR KR1020217015802A patent/KR20210097117A/en active Search and Examination
- 2019-11-29 JP JP2020557882A patent/JPWO2020111271A1/en active Pending
-
2023
- 2023-07-24 US US18/225,377 patent/US20230364006A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160206551A1 (en) * | 2015-01-15 | 2016-07-21 | William K. Boss, Jr. | Methods for the repair and rejuvenation of tissues using platelet-rich plasma compositions |
Non-Patent Citations (2)
Title |
---|
Fernandes et al (Cytotechnology, 2014, volume 68, pages 223-228) (Year: 2014) * |
Li et al (J Invest Dermatol, 2015, volume 135, pages 2181-2188) (Year: 2015) * |
Also Published As
Publication number | Publication date |
---|---|
CN113164783A (en) | 2021-07-23 |
TW202038976A (en) | 2020-11-01 |
JPWO2020111271A1 (en) | 2021-10-14 |
SG11202105105SA (en) | 2021-06-29 |
EP3888756A4 (en) | 2022-07-13 |
EP3888756A1 (en) | 2021-10-06 |
WO2020111271A1 (en) | 2020-06-04 |
US20230364006A1 (en) | 2023-11-16 |
KR20210097117A (en) | 2021-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kim et al. | Exosome‐guided phenotypic switch of M1 to M2 macrophages for cutaneous wound healing | |
Amos et al. | Human adipose-derived stromal cells accelerate diabetic wound healing: impact of cell formulation and delivery | |
Di Rocco et al. | Enhanced healing of diabetic wounds by topical administration of adipose tissue-derived stromal cells overexpressing stromal-derived factor-1: biodistribution and engraftment analysis by bioluminescent imaging | |
US20210010034A1 (en) | Transient cellular reprogramming for reversal of cell aging | |
Dai et al. | Restoration of skin pigmentation after deep partial or full-thickness burn injury | |
KR102360077B1 (en) | Composition for Improving Skin Comprising Exosomes Isolated from Umbilical Cord Derived Mesenchymal Stem Cell | |
Wang et al. | The effect of adipose-derived stem cells on full-thickness skin grafts | |
Zhang et al. | Integrating zinc/silicon dual ions with 3D-printed GelMA hydrogel promotes in situ hair follicle regeneration | |
US20230364006A1 (en) | Composition for treating or preventing skin pigmentation | |
JPWO2019178296A5 (en) | ||
US20220025337A1 (en) | Pigmentation skin model and method for producing same, and method for evaluating factor for treating or preventing pigmentation of skin | |
KR100701297B1 (en) | Culture Method of Fibroblast Using Placenta Extract and Composition for Skin Regeneration Using the Same | |
WO2007061205A1 (en) | Culture method of fibroblast using placenta extract and composition for skin regeneration using the same | |
KR100725133B1 (en) | Culture method of fibroblast using autologous serum mixed with placenta extract and composition for skin regeneration using the same | |
CN115461059A (en) | Compositions and methods relating to exosomes derived from human dermal papilla cells | |
KR102384953B1 (en) | Method for producing spheroid using matrilin-3 primed stem cells, and an substance for treating cartilage disease obtained thereof | |
RU2801316C2 (en) | Transient cellular reprogramming to reverse cell aging | |
EP4052718A1 (en) | Therapy for interstitial cystitis by pluripotent stem cells | |
Guo et al. | Injectable Small Intestinal Submucosa and Adipose-Derived Stem Cells Composite Gel Promoting The Deep Partial-Thickness Burns Repair | |
Nanic et al. | In Vivo Skin Regeneration and Wound Healing Using Cell Micro-Transplantation. Pharmaceutics 2022, 14, 1955 | |
Xu et al. | Experimental study on inhibitory effect of niacinamide on tumor necrosis factor-alpha-induced matrix degradation of annulus fibrous tissue in vitro | |
WO2022254075A1 (en) | Mesenchymal stem cells with increased therapeutic potential for the treatment of cancer | |
Limandjaja et al. | VU Research Portal | |
이애리 | Hair Growth Promoting Effect of Dermal Papilla Like Tissues from Canine Adipose-Derived Mesenchymal Stem Cells in Athymic Nude Mice | |
Zhang et al. | Research Article Erythropoietin Modification Enhances the Protection of Mesenchymal Stem Cells on Diabetic Rat-Derived Schwann Cells: Implications for Diabetic Neuropathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SHISEIDO COMPANY, LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOIDE, SAYAKA;TAKAGI, MASAYA;YAMADA, SHOKO;AND OTHERS;SIGNING DATES FROM 20210401 TO 20210414;REEL/FRAME:056388/0077 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |